CYCLIN-DEPENDENT KINASE INHIBITOR, PALBOCICLIB – A NEW DRUG FOR THE TREATMENT OF METASTATIC BREAST CANCER

The sequential use of several lines of endocrine therapy is considered the standard for the treatment of metastatic breast cancer, expressing estrogen or progesterone receptors. PALOMA-1, -2 and -3 studies showed that the combination of the inhibitor of CDK4/6, palbociclib, with endocrine therapy si...

Full description

Bibliographic Details
Main Authors: E. N. Imyanitov, T. Yu. Semiglazova
Format: Article
Language:Russian
Published: ABV-press 2017-12-01
Series:Опухоли женской репродуктивной системы
Subjects:
Online Access:https://ojrs.abvpress.ru/ojrs/article/view/561
_version_ 1826557254936035328
author E. N. Imyanitov
T. Yu. Semiglazova
author_facet E. N. Imyanitov
T. Yu. Semiglazova
author_sort E. N. Imyanitov
collection DOAJ
description The sequential use of several lines of endocrine therapy is considered the standard for the treatment of metastatic breast cancer, expressing estrogen or progesterone receptors. PALOMA-1, -2 and -3 studies showed that the combination of the inhibitor of CDK4/6, palbociclib, with endocrine therapy significantly increases the time to progression compared to the use of monotherapy with antagonists of the estrogen signaling cascade.
first_indexed 2024-04-10T01:56:06Z
format Article
id doaj.art-10144e1462404eff8595e3c3949344de
institution Directory Open Access Journal
issn 1994-4098
1999-8627
language Russian
last_indexed 2025-03-14T08:25:41Z
publishDate 2017-12-01
publisher ABV-press
record_format Article
series Опухоли женской репродуктивной системы
spelling doaj.art-10144e1462404eff8595e3c3949344de2025-03-02T13:05:34ZrusABV-pressОпухоли женской репродуктивной системы1994-40981999-86272017-12-01134344310.17650/1994-4098-2017-13-4-34-43553CYCLIN-DEPENDENT KINASE INHIBITOR, PALBOCICLIB – A NEW DRUG FOR THE TREATMENT OF METASTATIC BREAST CANCERE. N. Imyanitov0T. Yu. Semiglazova1N.N. Petrov National Medical Research Center of Onclology, Ministry of Health of Russia; Saint Petersburg State Pediatric Medical University, Ministry of Health of RussiaN.N. Petrov National Medical Research Center of Onclology, Ministry of Health of Russia; I.I. Mechnikov North-Western State Medical University Ministry of Health of RussiaThe sequential use of several lines of endocrine therapy is considered the standard for the treatment of metastatic breast cancer, expressing estrogen or progesterone receptors. PALOMA-1, -2 and -3 studies showed that the combination of the inhibitor of CDK4/6, palbociclib, with endocrine therapy significantly increases the time to progression compared to the use of monotherapy with antagonists of the estrogen signaling cascade.https://ojrs.abvpress.ru/ojrs/article/view/561metastatic er-positive breast cancerfactors of poor prognosisresistancehormonal therapypalbociclib
spellingShingle E. N. Imyanitov
T. Yu. Semiglazova
CYCLIN-DEPENDENT KINASE INHIBITOR, PALBOCICLIB – A NEW DRUG FOR THE TREATMENT OF METASTATIC BREAST CANCER
Опухоли женской репродуктивной системы
metastatic er-positive breast cancer
factors of poor prognosis
resistance
hormonal therapy
palbociclib
title CYCLIN-DEPENDENT KINASE INHIBITOR, PALBOCICLIB – A NEW DRUG FOR THE TREATMENT OF METASTATIC BREAST CANCER
title_full CYCLIN-DEPENDENT KINASE INHIBITOR, PALBOCICLIB – A NEW DRUG FOR THE TREATMENT OF METASTATIC BREAST CANCER
title_fullStr CYCLIN-DEPENDENT KINASE INHIBITOR, PALBOCICLIB – A NEW DRUG FOR THE TREATMENT OF METASTATIC BREAST CANCER
title_full_unstemmed CYCLIN-DEPENDENT KINASE INHIBITOR, PALBOCICLIB – A NEW DRUG FOR THE TREATMENT OF METASTATIC BREAST CANCER
title_short CYCLIN-DEPENDENT KINASE INHIBITOR, PALBOCICLIB – A NEW DRUG FOR THE TREATMENT OF METASTATIC BREAST CANCER
title_sort cyclin dependent kinase inhibitor palbociclib a new drug for the treatment of metastatic breast cancer
topic metastatic er-positive breast cancer
factors of poor prognosis
resistance
hormonal therapy
palbociclib
url https://ojrs.abvpress.ru/ojrs/article/view/561
work_keys_str_mv AT enimyanitov cyclindependentkinaseinhibitorpalbociclibanewdrugforthetreatmentofmetastaticbreastcancer
AT tyusemiglazova cyclindependentkinaseinhibitorpalbociclibanewdrugforthetreatmentofmetastaticbreastcancer